{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:30:30Z","timestamp":1762918230120,"version":"3.40.5"},"reference-count":60,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythaemia vera is one of several classical myeloproliferative neoplasms that may occur in a juvenile onset or late\u2010onset adult forms. It is linked to specific genetic mutations that cause a deleterious elevation in the patient\u2019s red cell mass. The discourse on genetics includes an expos\u00e9 on the molecular biology of the disease and how a shared <jats:italic>JAK2 V617F<\/jats:italic> mutation can co\u2010exist among three distinct neoplasms. Concepts of genetics and immunology help define the origin and behaviour of the disease: the tracking of allele burdens of mutations (genetic dosage), the timing or order of acquired mutations, the import of bystander mutations and the onco\u2010inflammatory response; all theories are invoked to explain the progression of disease severity and potential transformational leukaemia. The World Health Organization\u2019s diagnostic criteria are accessed to focus on the subtleties of the Hb laboratories and sifting through the challenging listing of differential diagnoses that mimic PV, and our report includes an overview of manual and automated phlebotomy (erythrocytapheresis) procedures, enumerating their clinical indications, significance of <jats:italic>temporary phlebotomy resistance<\/jats:italic> and optimizing safety\/ efficacy, quality and cost. Stratification of low and high\u2010risk disease distinguishes when to commence chemo\u2010cytoreductive therapy in the high\u2010risk patient to prevent thrombotic complications. <jats:italic>Drug resistance<\/jats:italic> is circumvented by artfully switching drugs or using novel drug designs.<\/jats:p>","DOI":"10.1111\/vox.13069","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T12:44:06Z","timestamp":1614343446000},"page":"617-627","source":"Crossref","is-referenced-by-count":7,"title":["Polycythaemia vera: molecular genetics, diagnostics and therapeutics"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-1225","authenticated-orcid":false,"given":"Jeffrey S.","family":"Putter","sequence":"first","affiliation":[{"name":"Medical Biomechanics Inc. North San Diego County, San Marcos CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[{"name":"International Consultancy in Innovative Manufacturing and Quality\/Safety of Blood \u2013 Derived Bioproducts London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-015-0256-1"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13886"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24183"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3211-7"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005143"},{"key":"e_1_2_13_9_1","first-page":"112","article-title":"JAK2 V617F. A single mutation in the myeloproliferative group of disorders","volume":"75","author":"McLornan D","year":"2006","journal-title":"Ulster Med J"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.00615.x"},{"key":"e_1_2_13_12_1","unstructured":"Lister Hill National Center for Biomedical Communications \u2010 Genetics Home Reference.https:\/\/ghr.nlm.nih.gov\/gene\/JAK2. [Last accessed 18 September 2018]."},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371328"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101576"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910397187"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712461047"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21645"},{"key":"e_1_2_13_19_1","unstructured":"Genetic Testing Registry National Center for Biotechnology Information https:\/\/www.ncbi.nlm.nih.gov\/gtr\/genes\/3716\/[accessed 7 September 2020]."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.079129"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001271"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25303"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412098"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000216"},{"key":"e_1_2_13_25_1","unstructured":"HemingwayTJ:Hyperviscosity syndrome. Emedicine\/Medscape. Available athttps:\/\/emedicine.medscape.com\/article\/780258\u2010overview[Last accessed 21 October 2018]."},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-009-0005-6"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23585"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.534"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1996.0024"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2019.1483"},{"key":"e_1_2_13_32_1","unstructured":"NagallaS BesaEC.Polycythemia vera. Emedicine\/Medscape.https:\/\/emedicine.medscape.com\/article\/205114\u2010overview[Last accessed 9 December 2019]."},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067348"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.06.010"},{"key":"e_1_2_13_36_1","first-page":"1017","article-title":"Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management","volume":"2011","author":"Tefferi A","year":"2012","journal-title":"Am J Hematol"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1187-3"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0758-y"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07220.x"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0199-5"},{"key":"e_1_2_13_41_1","unstructured":"Veterans Administration Medical Center San Diego \u2010 Personal communication with the infusion service. November 2019."},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21303"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0304-9"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1997.tb00028.x"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.09.017"},{"key":"e_1_2_13_48_1","unstructured":"HYDREA (hydroxyurea) highlights of prescribing informationhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/016295Orig1s047 s048Lbl.pdf[accessed 30 November 2020]."},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2152-7"},{"key":"e_1_2_13_50_1","unstructured":"National Library of Medicine.Pubchem.https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/busulfan[accessed 30 August 2020."},{"key":"e_1_2_13_51_1","unstructured":"Highlights of prescribing information. Busulfex (busulphan) for injection 18 Jun 2014https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020954s014lbl.pdf[accessed 30 August 2020."},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163"},{"key":"e_1_2_13_53_1","unstructured":"PEGASYS (peginterferon alfa\u20102a)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/pegihof101602LB.htm[accessed 24 September 2020]."},{"key":"e_1_2_13_54_1","unstructured":"Manufacturer\u2019s site. Jakafi (ruxolitinib) targets a primary driver of polycyhthemia vera. Mechanism of action.https:\/\/hcp.jakafi.com\/polycythemia\u2010vera\/pathophysiology\u2010moa[accessed 7 December 2020]."},{"key":"e_1_2_13_55_1","unstructured":"Genetic Testing Registry National Center for Biotechnology Information https:\/\/www.ncbi.nlm.nih.gov\/gtr\/genes\/3717\/[accessed 16 September 2020]."},{"key":"e_1_2_13_56_1","first-page":"75","article-title":"Jakafi (ruxolitinib). First FDA\u2010approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler LA","year":"2015","journal-title":"Am Health and Drug Benefits"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep14538"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01205-x"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.6884"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01648884"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(00)00042-4"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:56:33Z","timestamp":1692633393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/vox.13069"],"URL":"https:\/\/doi.org\/10.1111\/vox.13069","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"type":"print","value":"0042-9007"},{"type":"electronic","value":"1423-0410"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}